Investors
Stock Information
INVESTOR OVERVIEW
A Pioneer in Drug Delivery
TAHO is the first company from Taiwan to obtain Japan PMDA approval for a self-developed new dosage form drug, Ondasensetron ODF.
WE STRIVE TO BE A LEADER IN DRUG DELIVERY INNOVATION
TAHO pharma is a commercial-stage pharmaceutical company. We focus on the development of new drug delivery systems, majorly in transdermal and transmucosal systems. Our headquarter is in Taipei, Taiwan since 2010.
TAHO portfolio includes Ondansetron OD Film for chemotherapy-induced nausea and vomiting in Japan, and several projects focusing on Anticoagulant and CNS indications such as Alzheimer's Disease, Epilepsy, Opioid Addiction and ADHD.
TAHO portfolio includes Ondansetron OD Film for chemotherapy-induced nausea and vomiting in Japan, and several projects focusing on Anticoagulant and CNS indications such as Alzheimer's Disease, Epilepsy, Opioid Addiction and ADHD.